氯化N,N,N-三甲基-2-[(2-甲基-1-羰基-2-丙烯基)氧代]乙铵聚合2-丙烯酰胺,氯化2-丙烯酸和N,N,N-三甲基-2-[(1-羰基-2-丙烯基)氧代]乙铵 | 70059-30-2

• 物质功能分类: 原料药 - 消化系统用药 - 抑制胃酸分泌药
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 氯化N,N,N-三甲基-2-[(2-甲基-1-羰基-2-丙烯基)氧代]乙铵聚合2-丙烯酰胺,氯化2-丙烯酸和N,N,N-三甲基-2-[(1-羰基-2-丙烯基)氧代]乙铵
• 中文别名: N"-甲基-N"-[2-[[(5-甲基-1H-咪唑-4-基)甲基]硫代]乙基]-N-氰基胍盐酸盐；N-氰基-N’-甲基-N''-[2-[[(5-甲基-1H-咪唑-4-基)甲基]硫基]乙基]胍单盐酸盐；N'-甲基-N"-[2-[[(5-甲基-1H-咪唑-4-基)甲基]硫代]乙基]-N-氰基胍盐酸盐；盐酸西咪替丁
• 英文名称: Cimetidine hydrochloride
• 英文别名: Cimetidinhydrochlorid；Cimetidin-HCl；cimetidine；1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine;hydron;chloride
• CAS: 70059-30-2；71989-90-7
• 化学式: C₁₀H₁₆N₆S*ClH
• 分子量: 288.804
• InChiKey: QJHCNBWLPSXHBL-UHFFFAOYSA-N

物化性质

• 溶解度：
  易溶于水，微溶于无水乙醇。

计算性质

• 辛醇/水分配系数(LogP)：
  1.02
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  114
• 氢给体数：
  4
• 氢受体数：
  4

安全信息

• WGK Germany：
  3
• 海关编码：
  2933290090

文献信息

• [EN] ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST AND COMBINATION THERAPIES<br/>[FR] CONJUGUÉS D'ANTICORPS COMPRENANT UN AGONISTE DU RÉCEPTEUR DE TYPE TOLL ET POLYTHÉRAPIES
  申请人：NOVARTIS AG

  公开号：WO2018198091A1

  公开（公告）日：2018-11-01

  Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies. In some embodiments, the conjugates are used in combination with a second therapeutic agent.

  本文提供了包含Toll样受体激动剂的抗体偶联物，以及利用这些偶联物治疗癌症的用途。在某些实施例中，这些偶联物包括抗HER2抗体。在某些实施例中，这些偶联物与第二治疗剂联合使用。
• METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS
  申请人：TUFTS MEDICAL CENTER

  公开号：US20160052982A1

  公开（公告）日：2016-02-25

  The present application provides methods for preparing soluble lipidated ligand agents comprising a ligand entity and a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling appropriate selection of components to assemble active agents for any given target of interest.

  本申请提供了制备可溶性脂质化配体药剂的方法，包括配体实体和脂质实体，并在某些实施例中提供了这些组分的相关参数，从而使得能够适当选择组分来组装出针对任何感兴趣的靶点的活性药剂。
• FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Corkey Britton Kenneth

  公开号：US20120289493A1

  公开（公告）日：2012-11-15

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R 1 , X 1 , X 2 , Y and R 2 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及一类为钠通道抑制剂的化合物，以及它们在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。在特定实施例中，该化合物的结构由式I给出： 其中Q、R1、X1、X2、Y和R2如本文所述，以及制备和使用该化合物的方法，以及含有该化合物的药物组合物。
• Co-administration of dopamine-receptor binding compounds
  申请人：Fernandes B. Prabhavathi

  公开号：US20070155720A1

  公开（公告）日：2007-07-05

  Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D 1 receptor agonist, and administering to the patient an effective amount of a dopamine D 2 receptor antagonist. Pharmaceutical compositions comprising a dopamine D 1 receptor agonist and a dopamine D 2 receptor antagonist are also described. The D 1 dopamine receptor agonist and the D 2 dopamine receptor antagonist can be administered to the patient in the same or in a different composition or compositions.

  描述了治疗患有神经、精神和精神障碍的患者的方法，包括向患者施用部分和/或全多巴胺D1受体激动剂的有效量，并向患者施用多巴胺D2受体拮抗剂的有效量。还描述了包含多巴胺D1受体激动剂和多巴胺D2受体拮抗剂的药物组合物。D1多巴胺受体激动剂和D2多巴胺受体拮抗剂可以以相同或不同的组合或组合物形式向患者施用。
• ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS
  申请人：Kasibhatla Rao Srinivas

  公开号：US20060223797A1

  公开（公告）日：2006-10-05

  Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders. Methods of synthesis and use of such compounds are also described and claimed.

  炔基吡咯并[2,3-d]嘧啶及相关类似物被描述并证明具有作为热休克蛋白90（HSP90）抑制剂的效用，用于治疗和预防各种HSP90介导的疾病。还描述和声明了这类化合物的合成和使用方法。